S-Class
2026-08-05 09:48:29
Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events
S-Class
2026-07-23 02:20:42
Arrowhead hits 52-week high as late-stage trial win marks “derisking event”